We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS has issued an updated contingency plan in case government funding runs out this week, covering FDA operations in case Congress fails to pass a stopgap measure funding the federal government from Oct. 1 through Dec. 3. Read More
Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), on Friday defended overriding the CDC’s own advisory panel, which voted the previous day not to recommend a Pfizer COVID-19 booster shot for people at high risk of contracting the disease in the workplace. Read More
The FDA continued its implementation of new authorities for certain over-the-counter (OTC) drugs on Friday when it posted a final administrative order for OTC sunscreens. Read More
Two foreign manufactures have been sent FDA warning letters, highlighting sloppy testing of over-the-counter (OTC) analgesics and inadmissible marketing. Read More
The Department of Defense (DoD) is over-reliant on foreign drug supply chains, a problem that could spell big trouble not only for the military, but the entire country, says a new report from the DOD’s Office of the Inspector General (OIG). Read More
A Centers for Disease Control and Prevention (CDC) expert panel yesterday voted 9 to 6 that people aged 18-49 with underlying health conditions should be eligible to receive a booster vaccine, but voted down, 6 to 9, recommending a booster shot for people in that age group at risk of contracting the coronavirus based on their workplace. Read More
A Delaware court ruled Wednesday that Takeda Pharmaceutical is liable for damages to AbbVie for failing to supply its hormone therapy Lupron Depot (leuprolide acetate for depot suspension) according to the contract. Read More
The Health Resources and Services Administration (HRSA) has sent letters to six pharmaceutical companies — AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics — letting them know their failure to comply with the 340B drug discount program has been referred to the Office of Inspector General at HHS. And several of the companies are pushing back. Read More
A federal court has ruled that the FDA must do more work on its regulation of compounding pharmacies before it can enforce a final standard issued last year. Read More